PD‐L1 and beyond: Immuno‐oncology in cytopathology

Over the past decade, immunotherapy has emerged as one of the most promising cancer treatments. Several monoclonal antibodies targeting the programmed death 1 (PD‐1)/ programmed death ligand‐1 (PD‐L1) pathway have been integrated into standard‐of‐care treatments for a wide range of cancer types. Alt...

Descripción completa

Detalles Bibliográficos
Autores principales: Iaccarino, Antonino, Salatiello, Maria, Migliatico, Ilaria, De Luca, Caterina, Gragnano, Gianluca, Russo, Maria, Bellevicine, Claudio, Malapelle, Umberto, Troncone, Giancarlo, Vigliar, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453493/
https://www.ncbi.nlm.nih.gov/pubmed/33955097
http://dx.doi.org/10.1111/cyt.12982

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453493/
https://www.ncbi.nlm.nih.gov/pubmed/33955097
http://dx.doi.org/10.1111/cyt.12982

Ejemplares similares